ABE9 fused to SpRY Cas9 nickase enables precise generation of bystander free mouse models

J Jun Kai Ong S Sayari Bhunia B Beate Hilbert V Vanessa Kirschner S Sascha Duglosz F Frank Zimmermann M Marc Freichel (Department of General Pharmacology, Pharmakologisches Institut, Universität Heidelberg) A Alex Cornean

Abstract

Abstract Point mutations cause many genetic disorders, but modelling them in organisms is technically challenging. Creating mouse models that mimic these mutations is crucial for establishing a causal relationship between mutations and disease phenotype, thereby supporting the development of therapeutic strategies. Adenine base editors (ABEs) can correct single-nucleotide variants (SNVs) in disease modelling without double-stranded breaks (DSBs) or donor DNA, achieving higher product purity than traditional Cas9 methods. Earlier ABE techniques faced issues like limited targetability, bystander editing, and off-target effects. By combining two editor advancements, we introduced and tested ABE9-SpRY, an improved ABE variant fused with a PAM-flexible SpRY-Cas9 nickase. Our results show that ABE9-SpRY effectively generates three out of four targeted A-to-G mutations in mouse embryos, achieving desired editing efficiencies of up to 96% in individual adult founder mice. Furthermore, we observe fewer off-target events at predicted DNA sites in mouse embryos and in an orthogonal R-loop assay compared with ABE8e-SpRY. ABE9-SpRY also enhances product purity in mouse embryos under pooled sgRNA injections and, as a proof-of-concept, at a single endogenous locus in human induced pluripotent stem cells (hiPSCs), relative to ABE8e-SpRY. Our findings support ABE9-SpRY’s precision at the loci tested and PAM-flexible versatility. Although performance remains sequence-dependent, these data support ABE9-SpRY as a PAM-flexible tool for generating precise point-mutation models where bystander editing is a concern.

Article Details

Volume / Issue Vol. 16, Issue 1
Published February 20, 2026
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (8)

J

Jun Kai Ong

S

Sayari Bhunia

B

Beate Hilbert

V

Vanessa Kirschner

S

Sascha Duglosz

F

Frank Zimmermann

M

Marc Freichel

Department of General Pharmacology, Pharmakologisches Institut, Universität Heidelberg

A

Alex Cornean